Abingworth, an international life sciences investment group, has held the final closing of its new Clinical Co-Development Fund at USD582 million.
Abingworth Clinical Co-Development Fund 2 (ACCD 2) was significantly oversubscribed, exceeding its target of USD350 million, and closed at its hard cap. Alongside the recent USD465 million Abingworth Bioventures 8 (ABV 8) fund, Abingworth has raised over USD1 billion in new funds to invest in life science companies in the US, UK and Continental Europe developing innovative therapeutics with potential to significantly improve human health.
The ACCD 2 fund provides finance for the development of late-stage clinical programmes from pharmaceutical and biotechnology companies. ACCD 2 will invest directly in late-stage product financing opportunities, as well as through its co-development portfolio companies Avillion (UK) and SFJ Pharmaceuticals (US).
Read more at Private Equity Wire
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.